Isolated atomoxetine (Strattera™) ingestions commonly result in toxicity

Journal of Emergency Medicine

Volumn 31, Issue 3, 2006, Pages 267-268

  LoVecchio, Frank ^a,b,c   Kashani, J ^a  

^a Banner Good Samaritan Regional Poison Center   (United States)

^b MARICOPA MEDICAL CENTER   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

ADHA; atomoxetine; attention deficit hyperactivity disorder; Strattera

Indexed keywords

ACTIVATED CARBON; ANTIEMETIC AGENT; ATOMOXETINE; BENZODIAZEPINE;

ADOLESCENT; ADULT; AGITATION; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; COGNITIVE DEFECT; DROWSINESS; DRUG OVERDOSE; EMERGENCY TREATMENT; GASTROINTESTINAL SYMPTOM; GRAND MAL SEIZURE; HUMAN; HYPERACTIVITY; INFANT; INGESTION; NEUROTOXICITY; PRIORITY JOURNAL; QT PROLONGATION; SYMPTOMATOLOGY; TACHYCARDIA; THROAT IRRITATION; TREATMENT OUTCOME; TREMOR; VOMITING;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD, PRESCHOOL; COGNITION DISORDERS; HUMANS; INFANT; OVERDOSE; POISON CONTROL CENTERS; PROPYLAMINES; RETROSPECTIVE STUDIES; TACHYCARDIA; VOMITING;

EID: 33748551975     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2005.12.024     Document Type: Article

References (6)

1. Michelson D., Faries D., Wernicke J., et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108 (2001) E83
2. Spencer T., Heiligenstein J.H., Biederman J., Faries D.E., Kratochvil C.J., Conners C.K., and Potter W.Z. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63 (2002) 1140-1147
3. Chalon S.A., Desager J.P., Desante K.A., et al. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther 73 (2003) 178-191
4. Sawant S., and Daviss S.R. Seizures and prolonged QTc with atomoxetine overdose. Am J Psychiatry 161 (2004) 757
5. Wernicke J.F., and Kratochvil C.J. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 63 Suppl 12 (2002) 50-55
6. Michelson D., Allen A.J., Busner J., et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159 (2002) 1896-1901